Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 6/20 | 0.43 |
| ▸ | RARB | P10826 | 4/20 | 0.43 |
| ▸ | RARA | P10276 | 3/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016394 | 0.95 | RARG (0.45) | RARGRARBRARATLR7LRRK2 | |
| SCHEMBL12632960 | 0.92 | RARA (0.43) | RARGRARBRARATLR7LRRK2 | |
| SCHEMBL12632931 | 0.90 | RARG (0.42) | RARGRARBRARATLR7LRRK2 | |
| SCHEMBL2012573 | 0.89 | RARA (0.40) | RARGRARBRARALRRK2HTR1A | |
| SCHEMBL12959455 | 0.88 | RARG (0.40) | RARGRARBRARALRRK2DRD2 | |
| SCHEMBL2015583 | 0.86 | HTR1A (0.44) | RARGRARBRARAHTR1AHTR7 | |
| SCHEMBL12805041 | 0.84 | KCNH2 (0.36) | RARGRARBRARALRRK2HTR1A | |
| SCHEMBL12805138 | 0.83 | RARA (0.36) | RARGRARBRARALRRK2HTR1A | |
| SCHEMBL12968935 | 0.82 | RARA (0.39) | RARGRARBRARAHTR1ADRD2 | |
| SCHEMBL2053466 | 0.79 | RARG (0.43) | RARGRARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| EP-2513057-B1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2513057-B1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2513057-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, SPHK2, S1PR3 | RARG 4187/4885RARB 4194/4885RARA 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.